SEC Form 4 · accession 0001209191-18-020737
HERON THERAPEUTICS, INC. /DE/ · HRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kimberly Manhard
Officer — Executive VP, Drug Development
Period of report
Mar 19, 2018
Accepted (ET)
Mar 19, 2018 · 7:24 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000818033
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 19, 2018 | M | 18,000 | $13.00 | A | 18,000 | D | |
| Common Stock | Mar 19, 2018 | S | 18,000 | $30.00 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F2 | $13.00 | Mar 19, 2018 | M | 18,000 | D | — | Dec 21, 2026 | Common Stock | 18,000 | 94,416 | D |
Explanation of responses
- F1The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed in March 2017.
- F2The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the date of grant (12/21/2016).